- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00752297
Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows (PT-03a)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Dose Pivotal Trial to Demonstrate the Safety and Efficacy of PurTox® for the Treatment of Glabellar Rhytides ("Frown Lines")
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, two-arm, single-dose study to evaluate the safety and efficacy of Mentor Purified Toxin for the treatment of glabellar rhytides. Approximately 400 subjects will be enrolled in the study. The subjects will be randomized 3:1 (300 Mentor Purified Toxin: 100 placebo) to receive either intramuscular injections of 30 U of Mentor Purified Toxin or placebo (preservative-free saline).
Injected subjects will be observed for 180 days of post treatment follow-up. Follow-up clinic visits are scheduled for post treatment days 3, 7, 14, 30, 60, 90, 120, 150, and 180.
The study will be conducted at up to ten clinical sites. Safety, tolerability, clinical efficacy, onset and duration of effect will be studied during the study
The effectiveness of Mentor Purified Toxin will be determined by the degree of frown line reduction, during maximum forced frown and at rest (neutral expression):
- as assessed live by the study doctor,
- as assessed live by the subject, and
- as assessed by an independent reviewer based on subject photographs
Frown lines are graded on level of severity based on this scale:
Severity
- Minimal (0)
- Mild (1)
- Moderate (2)
- Severe (3)
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Santa Barbara, California, United States, 93111
- Mentor Worldwide, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects who are 18 years of age or older (subjects should have an interest in the effacement of glabellar rhytides) with or without previous botulinum Toxin Type A exposure;
- In good physical and mental health as determined by the investigator based on medical history, physical examination, and/or clinical laboratory tests;
- Noticeable presence of the glabellar rhytides for a period of 6 months or longer;
- Score at least a 2 (moderate severity) at baseline screening on the investigator's and subject's assessments (reference photographs provided) at forced frown; and
- Capable of understanding and complying with the protocol and must have signed the informed consent document prior to performance of any study-related procedures.
Exclusion Criteria:
- History of psychiatric problems that, in the investigator's opinion, is severe enough potentially to interfere with subject outcomes;
- History of autoimmune disease, that, in the opinion of the investigator, might interfere with subject outcomes (e.g., osteoarthritis is not considered an exclusion criteria; however, subjects with dermatomyositis are not permitted to participate in this study);
- History or presence of clinically significant cardiovascular, respiratory, hepatic/biliary, renal, gastrointestinal, endocrinological, or neurological disorders constituting a possible risk factor that, in the investigator's opinion, is severe enough potentially to interfere with subject outcomes;
- Inability to substantially efface glabellar lines by manually spreading skin apart;
- Eyelid ptosis;
- Myasthenia gravis (from medical history or diseases of neurotransmission);
- Current history of facial nerve paralysis;
- Concurrent dermatologic disease of the face in the glabellar area that is deemed by the investigator to make the subject an inappropriate candidate for the study;
- Recent flu-like syndrome that, in the investigator's opinion, is severe enough potentially to interfere with subject outcomes;
- Neuromuscular disorder that, in the investigator's opinion, is severe enough potentially to interfere with subject outcomes;
- Active multisystems disease that, in the investigator's opinion, might influence the outcome measures or the safety of the subject;
- Has any condition(s) that in the investigator's opinion would a) warrant exclusion from the study, or b) prevent the subject from completing the study;
- Currently receiving aminoglycoside antibiotic therapy, curare-like drugs, quinidine, succinylcholine, polymyxins, anticholinesterases, magnesium sulfate, or lincosamides;
- Has taken any investigational drug during the 30 days prior to screening visit;
- Have had Botulinum Toxin treatments to the glabellar and/or forehead area during the 6 months prior to screening visit;
- Have had dermal filler treatment to glabellar area during the 6 months prior to screening visit;
- Female subjects who are pregnant or lactating. (Female subjects of childbearing potential must have negative urine pregnancy test results prior to enrollment into the study. Such subjects, including peri-menopausal women who have had a menstrual period within one year, must use appropriate birth control (see protocol/informed consent for description)
- Unwilling or unable to comply with the protocol or to cooperate fully with the investigator and site personnel; and
- Unable to understand verbal and/or written English or any other language in which a certified translation of the informed consent document is available.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Mentor Purified Toxin Botulinum Toxin Type A
|
All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit.
The total treatment dose (sum of the five injections) to be administered will be 30 U of PurTox.
Subjects will have many Treatment Visits throughout the course of the three-year study.
Other Names:
|
Placebo Comparator: 2
Preservative-free Saline
|
Subjects will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle.
The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measurement of the incidences of treatment-emergent adverse events, serious treatment-emergent adverse events, treatment-emergent laboratory abnormalities, and vital signs.
Time Frame: Throughout
|
Throughout
|
Degree of glabellar rhytide reduction assessed by the investigator and the subject at maximum frown as a single composite effectiveness endpoint.
Time Frame: Day 30 post-injection
|
Day 30 post-injection
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Degree of glabellar rhytide reduction assessed by the investigator and the subject at maximum frown.
Time Frame: Days 3, 7 and 30 post-injection
|
Days 3, 7 and 30 post-injection
|
Degree of glabellar rhytide reduction assessed by the investigator and the subject at rest.
Time Frame: Day 30 Post-injection
|
Day 30 Post-injection
|
Degree of glabellar rhytide reduction assessed by independent reviewers based on photographs of the subject's glabellar lines at maximum frown.
Time Frame: Baseline and Day 30 post-injection
|
Baseline and Day 30 post-injection
|
Explore the global satisfaction of the subject with the treatment.
Time Frame: Day 30 post-injection
|
Day 30 post-injection
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Corey Maas, MD
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PT-03a
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glabellar Rhytides
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States
-
AllerganCompleted
-
AllerganCompletedGlabellar Rhytides | Forehead RhytidesUnited States, Canada, Ireland
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar Rhytides | Frown Lines Between the EyebrowsUnited States
-
AllerganCompletedFacial Rhytides | Glabellar RhytidesUnited States, Belgium, Germany, United Kingdom
-
AllerganCompletedGlabellar Frown Lines | Facial RhytidesCanada
-
Mohamed Hayder Oleish SalihCompletedGlabellar Frown Lines | Wrinkle | Facial Expression | RhytidesEgypt
-
AllerganCompletedGlabellar Lines | Crow's Feet Lines | Facial RhytidesGermany, Canada, United States, France
-
AllerganCompletedGlabellar Lines | Crow's Feet Lines | Facial RhytidesGermany, Canada, United States, France
-
AllerganCompletedGlabellar Lines | Nasolabial Fold | Crow's Feet Lines | Facial RhytidesUnited States
Clinical Trials on Mentor Purified Toxin
-
Mentor Worldwide, LLCCompletedSpasmodic TorticollisUnited States
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar Rhytides | Frown Lines Between the EyebrowsUnited States
-
Kinetic MusclesEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Oregon Health and Science UniversityCompleted
-
Cornell UniversityNelson Mandela African Institute of Science and Technology; Action Aid Tanzania and other collaboratorsCompletedMalnutrition
-
Johns Hopkins Bloomberg School of Public HealthCompletedHepatitis C | HIV | Risk Reduction BehaviorUnited States
-
Yale UniversityEli Lilly and Company; Connecticut State, Department of Mental Health and Addiction...CompletedSchizophrenia | Schizoaffective Disorder | Bipolar Disorder | Psychotic DepressionUnited States
-
NYU Langone HealthNational Institute on Disability, Independent Living, and Rehabilitation... and other collaboratorsRecruiting
-
University of Wisconsin, MadisonNational Center for Research Resources (NCRR)Completed